119 related articles for article (PubMed ID: 20461809)
21. A study of salivary secretion in Parkinson's disease.
Bagheri H; Damase-Michel C; Lapeyre-Mestre M; Cismondo S; O'Connell D; Senard JM; Rascol O; Montastruc JL
Clin Neuropharmacol; 1999; 22(4):213-5. PubMed ID: 10442250
[TBL] [Abstract][Full Text] [Related]
22. Understanding Parkinson's disease: an update on current diagnostic and treatment strategies.
Pahwa R
J Am Med Dir Assoc; 2006 Sep; 7(7 Suppl 2):4-10. PubMed ID: 17948613
[TBL] [Abstract][Full Text] [Related]
23. Surface electromyography shows increased mirroring in Parkinson's disease patients without overt mirror movements.
Cincotta M; Giovannelli F; Borgheresi A; Balestrieri F; Vanni P; Ragazzoni A; Zaccara G; Ziemann U
Mov Disord; 2006 Sep; 21(9):1461-5. PubMed ID: 16705686
[TBL] [Abstract][Full Text] [Related]
24. Analysis of the course of Parkinson's disease under dopaminergic therapy: performance of "fast tapping" is not a suitable parameter.
Kraus PH; Klotz P; Hoffmann A; Lewe J; Przuntek H
Mov Disord; 2005 Mar; 20(3):348-54. PubMed ID: 15584027
[TBL] [Abstract][Full Text] [Related]
25. Endocannabinoids in chronic migraine: CSF findings suggest a system failure.
Sarchielli P; Pini LA; Coppola F; Rossi C; Baldi A; Mancini ML; Calabresi P
Neuropsychopharmacology; 2007 Jun; 32(6):1384-90. PubMed ID: 17119542
[TBL] [Abstract][Full Text] [Related]
26. [The role of dopaminagonists in the treatment of Parkinson's disease].
Ransmayr G
Praxis (Bern 1994); 2005 Oct; 94(42):1633-8. PubMed ID: 16277084
[TBL] [Abstract][Full Text] [Related]
27. Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward.
Evans AH; Lawrence AD; Cresswell SA; Katzenschlager R; Lees AJ
Mov Disord; 2010 May; 25(7):867-76. PubMed ID: 20461804
[TBL] [Abstract][Full Text] [Related]
28. Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study.
Oertel WH; Wolters E; Sampaio C; Gimenez-Roldan S; Bergamasco B; Dujardin M; Grosset DG; Arnold G; Leenders KL; Hundemer HP; Lledó A; Wood A; Frewer P; Schwarz J
Mov Disord; 2006 Mar; 21(3):343-53. PubMed ID: 16211594
[TBL] [Abstract][Full Text] [Related]
29. Levodopa improves time-based prospective memory in Parkinson's disease.
Costa A; Peppe A; Brusa L; Caltagirone C; Gatto I; Carlesimo GA
J Int Neuropsychol Soc; 2008 Jul; 14(4):601-10. PubMed ID: 18577289
[TBL] [Abstract][Full Text] [Related]
30. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease.
Paus S; Grünewald A; Klein C; Knapp M; Zimprich A; Janetzky B; Möller JC; Klockgether T; Wüllner U
Mov Disord; 2008 Mar; 23(4):599-602. PubMed ID: 18175338
[TBL] [Abstract][Full Text] [Related]
31. Experimental parkinsonism alters anandamide precursor synthesis, and functional deficits are improved by AM404: a modulator of endocannabinoid function.
Fernandez-Espejo E; Caraballo I; Rodriguez de Fonseca F; Ferrer B; El Banoua F; Flores JA; Galan-Rodriguez B
Neuropsychopharmacology; 2004 Jun; 29(6):1134-42. PubMed ID: 15010694
[TBL] [Abstract][Full Text] [Related]
32. Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence.
de Lago E; de Miguel R; Lastres-Becker I; Ramos JA; Fernández-Ruiz J
Brain Res; 2004 May; 1007(1-2):152-9. PubMed ID: 15064146
[TBL] [Abstract][Full Text] [Related]
33. Treatment of Parkinson's disease and restless legs syndrome with cabergoline, a long-acting dopamine agonist.
Porter MC; Appiah-Kubf LS; Chaudhuri KR
Int J Clin Pract; 2002; 56(6):468-74. PubMed ID: 12166546
[TBL] [Abstract][Full Text] [Related]
34. Abnormal excitability of premotor-motor connections in de novo Parkinson's disease.
Buhmann C; Gorsler A; Bäumer T; Hidding U; Demiralay C; Hinkelmann K; Weiller C; Siebner HR; Münchau A
Brain; 2004 Dec; 127(Pt 12):2732-46. PubMed ID: 15509619
[TBL] [Abstract][Full Text] [Related]
35. [Impulsive-compulsive syndrome in Parkinson's disease].
Nikitina AV; Fedorova NV
Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(7 Pt 2):32-8. PubMed ID: 23994929
[TBL] [Abstract][Full Text] [Related]
36. Quantitative profiling of endocannabinoids and related
Kantae V; Ogino S; Noga M; Harms AC; van Dongen RM; Onderwater GL; van den Maagdenberg AM; Terwindt GM; van der Stelt M; Ferrari MD; Hankemeier T
J Lipid Res; 2017 Mar; 58(3):615-624. PubMed ID: 27999147
[TBL] [Abstract][Full Text] [Related]
37. Dopaminergic agonists in the treatment of Parkinson's disease: a review.
Piccoli F; Riuggeri RM
J Neural Transm Suppl; 1995; 45():187-95. PubMed ID: 8748625
[TBL] [Abstract][Full Text] [Related]
38. Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid.
Koethe D; Schreiber D; Giuffrida A; Mauss C; Faulhaber J; Heydenreich B; Hellmich M; Graf R; Klosterkötter J; Piomelli D; Leweke FM
J Neural Transm (Vienna); 2009 Mar; 116(3):301-5. PubMed ID: 19137236
[TBL] [Abstract][Full Text] [Related]
39. Up-regulation of anandamide levels as an endogenous mechanism and a pharmacological strategy to limit colon inflammation.
D'Argenio G; Valenti M; Scaglione G; Cosenza V; Sorrentini I; Di Marzo V
FASEB J; 2006 Mar; 20(3):568-70. PubMed ID: 16403786
[TBL] [Abstract][Full Text] [Related]
40. Combination of two different dopamine agonists in the management of Parkinson's disease.
Stocchi F; Berardelli A; Vacca L; Thomas A; De Pandis MF; Modugno N; Valente M; Ruggieri S
Neurol Sci; 2002 Sep; 23 Suppl 2():S115-6. PubMed ID: 12548370
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
